ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).

被引：4
|
作者：
Armstrong, Andrew J.
Szmulewitz, Russell Zelig
Petrylak, Daniel Peter
Holzbeierlein, Jeffrey M.
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris Yakovlevich
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Baron, Benoit
Chen, Lucy F.
Stenzl, Arnulf
机构：
[1] Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[4] Univ Kansas, Med Ctr, Westwood, KS USA
[5] Lille Univ, Univ Hosp Ctr, Dept Urol, Lille, France
[6] Monash Hlth, Melbourne, Vic, Australia
[7] Hosp Clin Barcelona, Dept Urol, Barcelona, Spain
[8] Hertzen Moscow Canc Res Inst, Moscow, Russia
[9] Osaka City Univ, Dept Urol, Grad Sch Med, Osaka, Japan
[10] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[11] Pfizer Inc, San Diego, CA USA
[12] Astellas Pharma Inc, Leiden, Netherlands
[13] Astellas Pharma Inc, Northbrook, IL USA
[14] Eberhard Karls Univ Tubingen, Univ Hosp, Dept Urol, Tubingen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5048
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial
    Saad, F.
    Vjaters, E.
    Shore, N. D.
    Olmos, D.
    Xing, N.
    Gomes, A. J. P. D. S.
    Mota, A. C. A.
    Salman, P.
    Jievaltas, M.
    Ulys, A.
    Jakubovskis, M.
    Kopyltsov, E.
    Han, W.
    Nevalaita, L.
    Testa, I.
    Le Berre, M-A.
    Kuss, I.
    Kunhiparambath, H.
    ANNALS OF ONCOLOGY, 2024, 35 : 1257 - 1258
  • [32] Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
    Sweeney, Christopher J.
    Martin, Andrew J.
    Stockler, Martin R.
    Begbie, Stephen
    Chi, Kim N.
    Chowdhury, Simon
    Coskinas, Xanthi
    Frydenberg, Mark
    Hague, Wendy E.
    Horvath, Lisa G.
    Joshua, Anthony M.
    Lawrence, Nicola J.
    Marx, Gavin M.
    McCaffrey, John
    McDermott, Ray
    McJannett, Margaret
    North, Scott A.
    Parnis, Francis
    Parulekar, Wendy
    Pook, David W.
    Reaume, M. Neil
    Sandhu, Shahneen K.
    Tan, Alvin
    Tan, Thean Hsiang
    Thomson, Alastair
    Tu, Emily
    Vera-Badillo, Francisco
    Williams, Scott G.
    Yip, Sonia
    Zhang, Alison Y.
    Zielinski, Robert R.
    Davis, Ian D.
    EUROPEAN UROLOGY, 2021, 80 (03) : 275 - 279
  • [33] Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Ito, Tetsuro
    Grant, Laura
    Duckham, Bryony R.
    Ribbands, Amanda J.
    Gater, Adam
    ADVANCES IN THERAPY, 2018, 35 (12) : 2186 - 2200
  • [34] Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Tetsuro Ito
    Laura Grant
    Bryony R. Duckham
    Amanda J. Ribbands
    Adam Gater
    Advances in Therapy, 2018, 35 : 2186 - 2200
  • [35] Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
    Gill, David Michael
    Stenehjem, David D.
    Cheng, Heather H.
    Kessler, Elizabeth Riley
    Hahn, Andrew W.
    Gupta, Sumati
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [36] Clinical outcomes of patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): Post hoc analysis of ARCHES
    Stenzl, A.
    Shore, N. D.
    Villers, A.
    Iguchi, T.
    Gomez-Veiga, F.
    Alcaraz, A.
    Alekseev, B.
    Azad, A. A.
    Szmulewitz, R. Z.
    Petrylak, D.
    Holzbeierlein, J.
    Rosbrook, B.
    Zohren, F.
    Haas, G. P.
    Gourgioti, G.
    El-Chaar, N. N.
    Armstrong, A. J.
    EUROPEAN UROLOGY, 2022, 81 : S776 - S777
  • [37] Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).
    Barata, Pedro C.
    Emamekhoo, Hamid
    Mendiratta, Prateek
    Gopalakrishnan, Dharmesh
    Koshkin, Vadim S.
    Tyler, Allison Janine
    Ornstein, Moshe Chaim
    Grivas, Petros
    Gilligan, Timothy D.
    Rini, Brian I.
    Kyriakopoulos, Christos
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [38] Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
    Sweeney, C. J.
    Martin, A. J.
    Stockler, M. R.
    Begbie, S.
    Chi, K. N.
    Chowdhury, S.
    Coskinas, X.
    Frydenberg, M.
    Hague, W. E.
    Horvath, L. G.
    Joshua, A. M.
    Lawrence, N. J.
    Marx, G. M.
    McCaffrey, J.
    McDermott, R.
    McJannett, M.
    North, S. A.
    Parnis, F.
    Parulekar, W.
    Pook, D. W.
    Reaume, M. N.
    Sandhu, S. K.
    Tan, A.
    Tan, T. H.
    Thomson, A.
    Tu, E.
    Vera-Badillo, F.
    Williams, S. G.
    Yip, S.
    Zhang, A. Y.
    Zielinski, R. R.
    Davis, I. D.
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1519 - 1520
  • [39] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Tan, Pui San
    Aguiar Jr, Pedro
    Haaland, Benjamin
    Lopes, Gilberto
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (04) : 516 - 523
  • [40] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Pui San Tan
    Pedro Aguiar
    Benjamin Haaland
    Gilberto Lopes
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 516 - 523
12345